Hub : Traits :

High cholesterol (Self-reported)

530 significantly associated models · 162 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	26327671	27895517	5	1	5.4e-10	1.8e-07	6.0e-01	99	PIGV
2	1	61510619	64021096	5	1	6.2e-23	4.9e-23	3.8e-02	96	DOCK7
3	1	108854166	111016796	13	9	4.5e-80	5.1e-80	1.0e+00	100	AMIGO1 ATXN7L2 CELSR2 GPSM2 GSTM1 PSRC1
4	2	20529948	21958745	1	1	2.1e-74	1.5e-76	1.0e+00	100	APOB
5	2	26624843	28607344	20	1	3.3e-36	3.2e-36	1.0e+00	100	FNDC4
6	2	43791363	44450524	2	2	2.8e-14	3.8e-39	1.6e-28	28	ABCG5 LRPPRC
7	2	202434393	204433184	4	1	9.8e-12	1.0e-10	4.4e-02	90	NOP58
8	3	11829474	13321852	2	2	2.2e-10	1.6e-09	3.2e-04	64	MKRN2 TSEN2
9	4	3054017	3688660	1	1	6.5e-08	2.8e-08	1.1e-04	51	RGS12
10	5	73626450	75704085	8	1	3.0e-38	4.0e-38	1.6e-03	94	HMGCR
11	6	159820779	161571560	3	4	5.5e-14	1.0e-23	4.2e-13	48	RP11-288H12.3 SLC22A1 SLC22A3
12	7	21222842	22188630	2	2	6.1e-08	5.0e-11	1.5e-01	95	DNAH11 SP4
13	7	43885849	45318389	3	2	1.0e-12	1.2e-13	3.0e-01	98	DDX56 NPC1L1
14	8	18003897	18505600	1	1	1.1e-09	7.5e-13	1.4e-04	72	NAT2
15	8	19064892	20521138	1	1	4.7e-12	1.1e-13	7.7e-05	72	LPL
16	8	58628032	60056887	1	1	1.7e-07	1.6e-11	3.5e-06	53	UBXN2B
17	9	106846396	108380721	1	1	4.1e-10	2.4e-14	9.9e-06	66	ABCA1
18	9	135883620	136399075	1	1	1.3e-16	3.1e-16	1.1e-04	78	ABO
19	11	60965461	62380732	1	1	2.4e-07	1.6e-05	8.1e-03	62	RAB3IL1
20	11	100168289	101559718	1	1	1.5e-07	1.5e-06	9.6e-01	100	TMEM133
21	11	115953897	117800682	7	10	1.5e-46	3.8e-51	NaN	NaN	BUD13 PAFAH1B2 PCSK7 SIDT2 SIK3 ZNF259
22	11	125979757	126556323	1	1	1.4e-09	7.2e-08	5.7e-04	59	ST3GAL4
23	12	120722064	122131468	3	2	3.8e-11	2.3e-13	3.4e-03	84	C12orf27 C12orf43
24	13	32275990	33700374	1	1	1.1e-07	9.6e-06	1.9e-01	91	N4BP2L1
25	16	71227328	72845749	7	8	1.2e-18	9.3e-18	1.0e+00	100	DHODH DHX38 HP TXNL4B
26	17	44788310	46474610	9	1	3.7e-09	4.3e-09	3.5e-01	97	MRPL45P2
27	17	73059836	74629867	8	1	3.1e-09	1.2e-10	3.5e-03	79	MRPL38
28	19	9982334	12196190	13	9	3.6e-38	2.8e-100	NaN	NaN	CARM1 KANK2 SMARCA4 SPC24
29	19	18533642	20451172	8	2	1.1e-15	3.6e-19	2.9e-05	78	ATP13A1
30	19	44190626	46098885	10	8	2.7e-30	4.7e-145	2.7e-31	79	APOC2 APOC4 BCAM CEACAM16 PVRL2 TOMM40 ZNF229 ZNF285
31	19	48464978	50108983	9	1	8.0e-17	3.4e-16	3.7e-02	94	NTN5
32	20	39270768	40683594	2	1	5.0e-10	4.5e-10	1.0e+00	100	ZHX3
33	20	61800907	62912463	5	1	1.1e-12	3.2e-12	2.6e-02	90	RGS19

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
LDL Cholesterol	50.39	53	39	86.7	0.95	2.7e-34	ABCA1 ABCG5 ABO AMIGO1 APOB APOC2 APOC4 ATP13A1 ATXN7L2 BCAM BUD13 C12orf27 C12orf43 CARM1 CEACAM16 CELSR2 DDX56 DHODH DHX38 DNAH11 DOCK7 FNDC4 GPSM2 GSTM1 HMGCR HP KANK2 LRPPRC MKRN2 MRPL45P2 N4BP2L1 NPC1L1 NTN5 PAFAH1B2 PCSK7 PIGV PSRC1 PVRL2 RAB3IL1 RGS12 RP11-288H12.3 SIDT2 SLC22A3 SMARCA4 SPC24 ST3GAL4 TOMM40 TSEN2 TXNL4B ZHX3 ZNF229 ZNF259 ZNF285
Triglycerides	31.08	16	13	28.9	0.82	6.5e-06	APOB ATP13A1 BUD13 DOCK7 FNDC4 LPL NAT2 PAFAH1B2 PCSK7 PVRL2 RGS12 SIDT2 SIK3 SLC22A3 TXNL4B ZNF259
Medication: Cholesterol lowering	21.80	48	30	66.7	0.99	6.7e-48	ABCG5 ABO AMIGO1 APOB APOC2 ATP13A1 ATXN7L2 BCAM BUD13 C12orf27 CEACAM16 CELSR2 DHODH DHX38 DOCK7 FNDC4 GPSM2 GSTM1 HMGCR HP KANK2 LPL LRPPRC MRPL45P2 NAT2 NOP58 NPC1L1 NTN5 PAFAH1B2 PCSK7 PIGV PSRC1 PVRL2 RGS19 RP11-288H12.3 SIDT2 SLC22A1 SLC22A3 SMARCA4 SPC24 ST3GAL4 TMEM133 TOMM40 TXNL4B UBXN2B ZHX3 ZNF229 ZNF259
Cholesterol lowering medication	19.21	46	27	60.0	0.99	1.0e-46	ABCA1 ABCG5 ABO AMIGO1 APOB APOC2 ATXN7L2 BCAM BUD13 C12orf27 C12orf43 CELSR2 DHODH DHX38 DOCK7 FNDC4 GPSM2 HMGCR HP KANK2 LPL LRPPRC N4BP2L1 NAT2 NOP58 NPC1L1 NTN5 PAFAH1B2 PCSK7 PIGV PSRC1 PVRL2 RAB3IL1 RGS19 SIDT2 SIK3 SLC22A3 SMARCA4 SPC24 TOMM40 TSEN2 TXNL4B ZHX3 ZNF229 ZNF259 ZNF285
Medication: Simvastatin	17.26	40	24	53.3	0.99	4.6e-38	ABCG5 ABO AMIGO1 APOB APOC2 ATP13A1 ATXN7L2 BCAM CELSR2 DHODH DHX38 DOCK7 FNDC4 GPSM2 GSTM1 HMGCR HP LPL LRPPRC MRPL45P2 NAT2 NOP58 NPC1L1 NTN5 PAFAH1B2 PCSK7 PIGV PSRC1 PVRL2 RAB3IL1 RGS19 SLC22A3 SMARCA4 SPC24 ST3GAL4 TMEM133 TOMM40 TXNL4B ZHX3 ZNF259
Medication: Atorvastatin	16.31	34	14	31.1	0.98	1.1e-28	ABCA1 ABO APOB ATP13A1 ATXN7L2 BCAM BUD13 C12orf27 C12orf43 CARM1 CELSR2 DOCK7 FNDC4 GPSM2 HMGCR KANK2 LPL LRPPRC PAFAH1B2 PCSK7 PSRC1 PVRL2 RGS19 SIK3 SLC22A1 SLC22A3 SMARCA4 SPC24 TOMM40 TXNL4B UBXN2B ZNF229 ZNF259 ZNF285
Alzheimer’s Disease (including proxy)	15.08	8	8	17.8	0.92	1.3e-03	APOC2 APOC4 BCAM CEACAM16 PVRL2 TOMM40 ZNF229 ZNF285
HDL Cholesterol	10.20	14	6	13.3	-0.49	6.5e-02	ABCA1 APOB APOC2 BUD13 CARM1 CELSR2 GPSM2 LPL PIGV PVRL2 RAB3IL1 SIDT2 TOMM40 ZNF259
Medication for cholesterol, blood pressure or diabetes	8.97	24	8	17.8	-0.95	1.0e-13	APOB ATXN7L2 BUD13 CELSR2 DHX38 FNDC4 HMGCR HP LPL LRPPRC NPC1L1 NTN5 PAFAH1B2 PCSK7 PSRC1 RGS19 SIDT2 SIK3 SLC22A1 SPC24 TMEM133 TOMM40 TXNL4B ZNF259
Cardiovascular Disease	8.55	43	30	66.7	0.94	9.6e-25	APOB APOC4 ATXN7L2 BCAM BUD13 C12orf27 CELSR2 DDX56 DHODH DHX38 DOCK7 FNDC4 HMGCR HP LPL MRPL38 MRPL45P2 NAT2 NOP58 NPC1L1 NTN5 PAFAH1B2 PCSK7 PIGV PSRC1 PVRL2 RGS12 RGS19 RP11-288H12.3 SIDT2 SIK3 SLC22A1 SLC22A3 SMARCA4 SPC24 TMEM133 TOMM40 TSEN2 TXNL4B UBXN2B ZNF229 ZNF259 ZNF285
Alzheimer’s Disease (in mother)	8.32	8	8	17.8	0.93	7.4e-04	APOC2 APOC4 BCAM CEACAM16 PVRL2 TOMM40 ZNF229 ZNF285
Illnesses of father: Heart disease	6.06	10	5	11.1	0.94	2.3e-06	CELSR2 LPL NPC1L1 PSRC1 RGS19 RP11-288H12.3 SLC22A1 SLC22A3 SPC24 ST3GAL4
Coronary Artery Disease (CAD)	5.97	8	3	6.7	0.95	7.6e-05	ATXN7L2 C12orf27 CELSR2 LPL PSRC1 SLC22A3 ST3GAL4 ZNF259
Medication for cholesterol	5.76	13	2	4.4	-0.92	1.6e-06	CELSR2 DHODH DHX38 FNDC4 GPSM2 HP NTN5 PCSK7 PIGV PSRC1 PVRL2 TMEM133 TXNL4B
Angina (self-reported)	5.48	9	4	8.9	0.95	3.3e-06	ABCG5 ATXN7L2 CELSR2 LPL PSRC1 RGS19 SLC22A1 SLC22A3 SPC24
Angina	5.16	10	2	4.4	0.94	6.6e-06	ABCG5 ATXN7L2 CELSR2 LPL PSRC1 RGS19 SLC22A1 SLC22A3 SPC24 TMEM133
Medication: Aspirin	4.19	7	1	2.2	0.89	2.9e-03	ATXN7L2 CELSR2 LPL PSRC1 RGS19 SLC22A1 SLC22A3
Heart attack	4.15	6	2	4.4	0.93	8.1e-03	CELSR2 LPL PSRC1 SLC22A1 SLC22A3 SPC24
Heart attack/myocardial infarction (self-reported)	4.09	7	2	4.4	0.93	2.5e-03	CELSR2 LPL PSRC1 SLC22A1 SLC22A3 SP4 SPC24
Medication: Aspirin	3.93	7	1	2.2	0.90	2.6e-03	ATXN7L2 CELSR2 LPL PSRC1 RGS19 SLC22A1 SLC22A3
Alzheimer’s Disease (in father)	3.69	6	3	6.7	0.96	2.9e-03	APOC2 APOC4 PVRL2 TOMM40 ZNF229 ZNF285
Heart disease (siblings)	3.32	2	1	2.2	0.00	1.0e+00	SLC22A1 SLC22A3
Number of self-reported non-cancer illnesses	3.31	4	1	2.2	0.98	1.8e-02	DHX38 FNDC4 NTN5 RGS19
Number of treatments/medications taken	3.27	8	1	2.2	0.92	5.2e-04	CELSR2 DHX38 FNDC4 HP NOP58 NTN5 PSRC1 TMEM133
Heart disease (mother)	2.99	2	1	2.2	0.00	1.0e+00	SLC22A1 SLC22A3
Blood Platelet Count	2.84	27	21	46.7	-0.23	2.0e-01	ABO APOC2 ATP13A1 BUD13 C12orf27 C12orf43 CARM1 DDX56 DOCK7 FNDC4 GSTM1 HMGCR HP NTN5 PAFAH1B2 PCSK7 PIGV RAB3IL1 RGS12 SIDT2 SIK3 TOMM40 TSEN2 TXNL4B ZHX3 ZNF259 ZNF285
Vascular/heart problems diagnosed by doctor	2.77	6	3	6.7	-0.92	9.6e-03	MRPL38 NPC1L1 NTN5 PIGV RGS19 TMEM133
Systolic Blood Pressure	2.68	14	8	17.8	0.80	3.5e-04	APOC4 FNDC4 MRPL38 NTN5 PAFAH1B2 PCSK7 PIGV RGS12 RGS19 SIDT2 SMARCA4 ST3GAL4 TMEM133 TOMM40
Medication: Atenolol	2.54	1	0	0.0	0.00	1.0e+00	TMEM133
Father's age at death	2.54	3	0	0.0	0.00	1.0e+00	ATXN7L2 CELSR2 LPL
Blood Red Count	2.49	12	9	20.0	-0.29	3.6e-01	ABCG5 ABO ATP13A1 C12orf27 DHODH FNDC4 HP MKRN2 PCSK7 PVRL2 TXNL4B ZHX3
Hypertension (Self-reported)	2.45	5	4	8.9	0.89	4.3e-02	MRPL38 NTN5 PIGV RGS19 TMEM133
Medication: Blood pressure	2.44	5	2	4.4	0.91	1.2e-02	DHX38 HP PIGV RGS19 TMEM133
High blood pressure	2.43	6	3	6.7	0.91	1.2e-02	MRPL38 NPC1L1 NTN5 PIGV RGS19 TMEM133
Medication: Blood pressure	2.42	4	1	2.2	0.93	7.0e-02	NPC1L1 NTN5 RGS19 TMEM133
Gout (self-reported)	2.38	1	1	2.2	0.00	1.0e+00	FNDC4
Waist Hip Ratio (WHR)	2.37	15	7	15.6	0.66	2.9e-03	ABCA1 ATP13A1 BUD13 CARM1 KANK2 LPL LRPPRC MKRN2 NTN5 RGS19 SIDT2 SLC22A3 SMARCA4 TSEN2 ZHX3
Illnesses of father: None of the above (group 1)	2.30	1	0	0.0	0.00	1.0e+00	SLC22A3
Illnesses of siblings	2.28	1	0	0.0	0.00	1.0e+00	TMEM133
Alcohol intake versus 10 years previously	2.27	3	2	4.4	0.00	1.0e+00	AMIGO1 FNDC4 NTN5
Medication: Ramipril	2.25	1	1	2.2	0.00	1.0e+00	TMEM133
Fasting Glucose	2.18	1	1	2.2	0.00	1.0e+00	FNDC4
Medication: Allopurinol	2.15	2	1	2.2	0.00	1.0e+00	FNDC4 PIGV
Alcohol intake frequency.	2.11	3	2	4.4	0.00	1.0e+00	FNDC4 NTN5 RGS12
Type 2 Diabetes (T2D) (2018)	2.08	3	1	2.2	0.00	1.0e+00	ATP13A1 FNDC4 LPL
Blood clot in the leg (DVT)	1.99	1	1	2.2	0.00	1.0e+00	ABO
Diabetes diagnosed by doctor	1.94	2	1	2.2	0.00	1.0e+00	ATP13A1 FNDC4
Osteoarthritis (self-reported)	1.93	1	0	0.0	0.00	1.0e+00	SMARCA4
Birth weight of first child	1.89	3	0	0.0	0.00	1.0e+00	ATP13A1 HP RGS19
Systolic blood pressure, automated reading	1.85	4	2	4.4	0.81	1.9e-01	PIGV RGS19 ST3GAL4 TMEM133
Medication: Metformin	1.85	2	1	2.2	0.00	1.0e+00	FNDC4 LPL
Deep venous thrombosis (DVT) (self-reported)	1.85	1	1	2.2	0.00	1.0e+00	ABO
High blood pressure (siblings)	1.84	1	0	0.0	0.00	1.0e+00	TMEM133
Diabetes (self-reported)	1.82	1	1	2.2	0.00	1.0e+00	FNDC4
Diastolic blood pressure, automated reading	1.80	4	1	2.2	0.18	8.2e-01	ABO PIGV RGS19 TMEM133
Diabetes (mother)	1.78	2	0	0.0	0.00	1.0e+00	ATP13A1 PVRL2
Pulse rate, automated reading	1.69	2	1	2.2	0.00	1.0e+00	FNDC4 KANK2
Pulse rate	1.67	1	1	2.2	0.00	1.0e+00	FNDC4
Rheumatoid Arthritis	1.66	1	0	0.0	0.00	1.0e+00	RGS19
BMI	1.66	14	6	13.3	-0.33	2.1e-01	AMIGO1 ATXN7L2 CEACAM16 DHODH DHX38 FNDC4 HMGCR HP MRPL38 NOP58 RGS12 SIDT2 SLC22A3 TXNL4B
Trunk fat-free mass	1.62	9	7	15.6	-0.88	1.6e-03	APOC4 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4 TMEM133
Hip circumference	1.62	11	5	11.1	-0.64	2.5e-02	ABCA1 CARM1 FNDC4 GSTM1 HMGCR MRPL38 NTN5 SLC22A3 SMARCA4 TSEN2 TXNL4B
Trunk predicted mass	1.62	9	7	15.6	-0.88	1.6e-03	APOC4 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4 TMEM133
Ovarian Cancer	1.60	2	0	0.0	0.00	1.0e+00	C12orf27 CARM1
Serious illness, injury or assault of a close relative in last 2 years	1.58	1	0	0.0	0.00	1.0e+00	NTN5
Whole body fat-free mass	1.58	10	6	13.3	-0.82	3.8e-03	APOC4 ATP13A1 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4 TMEM133
Leg predicted mass (left)	1.57	9	5	11.1	-0.82	7.4e-03	APOC4 ATP13A1 ATXN7L2 CARM1 FNDC4 HMGCR MRPL38 SLC22A3 SMARCA4
Leg fat-free mass (right)	1.57	9	6	13.3	-0.76	1.1e-02	APOC4 ATP13A1 ATXN7L2 FNDC4 HMGCR MRPL38 SLC22A3 SMARCA4 TMEM133
Whole body water mass	1.57	10	6	13.3	-0.81	4.1e-03	APOC4 ATP13A1 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4 TMEM133
Leg fat-free mass (left)	1.56	9	5	11.1	-0.82	7.4e-03	APOC4 ATP13A1 ATXN7L2 CARM1 FNDC4 HMGCR MRPL38 SLC22A3 SMARCA4
Leg predicted mass (right)	1.56	9	5	11.1	-0.76	1.1e-02	APOC4 ATP13A1 ATXN7L2 FNDC4 HMGCR MRPL38 SLC22A3 SMARCA4 TMEM133
Arm fat mass (right)	1.55	8	2	4.4	-0.23	5.8e-01	DHX38 FNDC4 GSTM1 HMGCR HP MRPL38 SLC22A3 TXNL4B
Arm predicted mass (left)	1.55	8	7	15.6	-0.90	2.5e-03	APOC4 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4
Arm fat percentage (right)	1.54	9	4	8.9	0.07	8.4e-01	ABO DHX38 GSTM1 HMGCR HP MRPL38 NOP58 SIDT2 TXNL4B
Basal metabolic rate	1.54	9	6	13.3	-0.82	6.5e-03	APOC4 ATP13A1 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4
Chest pain or discomfort	1.53	1	0	0.0	0.00	1.0e+00	MRPL45P2
Arm fat percentage (left)	1.53	10	4	8.9	-0.04	9.0e-01	ABO DHX38 GSTM1 HMGCR HP MRPL38 NOP58 PVRL2 SIDT2 TXNL4B
Arm fat mass (left)	1.53	8	2	4.4	-0.23	5.9e-01	DHX38 FNDC4 GSTM1 HMGCR HP MRPL38 SLC22A3 TXNL4B
Weight	1.51	12	3	6.7	-0.66	2.0e-02	APOC4 ATXN7L2 CARM1 DHX38 FNDC4 GSTM1 HMGCR MRPL38 NTN5 SLC22A3 SMARCA4 TXNL4B
Arm fat-free mass (right)	1.51	8	6	13.3	-0.89	3.0e-03	APOC4 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4
Blood White Count	1.50	11	4	8.9	0.08	8.0e-01	ABO ATP13A1 CARM1 DOCK7 FNDC4 MRPL38 PAFAH1B2 PVRL2 SMARCA4 TMEM133 TSEN2
Medication: Bendroflumethiazide	1.49	2	1	2.2	0.00	1.0e+00	PIGV TMEM133
Blood Eosinophil Count	1.48	16	10	22.2	-0.43	7.2e-02	ABO APOC2 ATP13A1 BCAM C12orf27 CARM1 LPL MRPL38 PAFAH1B2 PIGV SIDT2 SMARCA4 ST3GAL4 TOMM40 TSEN2 ZNF259
Comparative height size at age 10	1.48	12	5	11.1	-0.51	7.5e-02	APOC4 ATP13A1 C12orf27 CELSR2 FNDC4 KANK2 MKRN2 NTN5 PIGV RGS12 SLC22A3 SPC24
Medication: Amlodipine	1.47	1	1	2.2	0.00	1.0e+00	TMEM133
Arm predicted mass (right)	1.47	8	5	11.1	-0.89	3.0e-03	APOC4 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4
Arm fat-free mass (left)	1.47	8	7	15.6	-0.89	3.2e-03	APOC4 ATXN7L2 CELSR2 FNDC4 HMGCR NTN5 SLC22A3 SMARCA4
Myopia	1.46	1	0	0.0	0.00	1.0e+00	KANK2
Leg fat mass (right)	1.45	8	1	2.2	-0.25	5.5e-01	DHX38 FNDC4 GSTM1 HMGCR HP MRPL38 SLC22A3 TXNL4B
Breast Cancer	1.44	4	1	2.2	0.42	5.8e-01	ABO ATP13A1 RGS19 SIDT2
Leg fat mass (left)	1.43	8	1	2.2	-0.27	5.1e-01	DHX38 FNDC4 GSTM1 HMGCR HP MRPL38 SLC22A3 TXNL4B
Diabetes (father)	1.42	1	0	0.0	0.00	1.0e+00	FNDC4
Body mass index (BMI)	1.42	7	2	4.4	-0.26	5.7e-01	DHX38 FNDC4 GSTM1 HMGCR HP PVRL2 TXNL4B
Whole body fat mass	1.41	7	3	6.7	-0.46	3.0e-01	DHX38 GSTM1 HMGCR MRPL38 PVRL2 SLC22A3 TXNL4B
Body fat percentage	1.40	10	2	4.4	-0.02	9.6e-01	BCAM C12orf43 DHX38 GSTM1 HMGCR HP MRPL38 NOP58 PVRL2 TXNL4B
Leg fat percentage (right)	1.39	6	1	2.2	0.16	7.6e-01	DHX38 GSTM1 HMGCR HP KANK2 NOP58
Back pain experienced in last month	1.39	1	0	0.0	0.00	1.0e+00	APOB
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.39	1	0	0.0	0.00	1.0e+00	PVRL2
Trunk fat mass	1.38	8	3	6.7	-0.25	5.5e-01	C12orf43 DHX38 GSTM1 HMGCR MRPL38 PVRL2 SLC22A3 TXNL4B
High blood pressure (mother)	1.37	2	1	2.2	0.00	1.0e+00	PIGV TMEM133
Waist circumference	1.37	6	1	2.2	-0.29	5.7e-01	DHX38 FNDC4 HMGCR HP PVRL2 TXNL4B
Leg fat percentage (left)	1.36	7	1	2.2	-0.04	9.4e-01	BCAM DHX38 GSTM1 HMGCR HP KANK2 NOP58
Impedance of leg (left)	1.35	9	6	13.3	0.40	2.5e-01	ABO AMIGO1 ATP13A1 ATXN7L2 CARM1 FNDC4 HMGCR RGS19 TMEM133
Bipolar Disorder (2018)	1.33	1	0	0.0	0.00	1.0e+00	FNDC4
Trunk fat percentage	1.33	9	2	4.4	-0.18	6.5e-01	C12orf43 DHX38 GSTM1 HMGCR MRPL38 NOP58 PVRL2 SLC22A3 TXNL4B
Respiratory disease	1.31	2	0	0.0	0.00	1.0e+00	ABO MRPL38
Crohns Disease (2017)	1.29	3	1	2.2	0.00	1.0e+00	DOCK7 FNDC4 NTN5
Smoking Status	1.29	2	0	0.0	0.00	1.0e+00	C12orf43 DHX38
Allergy or Eczema	1.28	5	1	2.2	0.32	5.9e-01	ABO C12orf27 C12orf43 FNDC4 PVRL2
Allergy	1.28	2	1	2.2	0.00	1.0e+00	ABO C12orf27
Forced vital capacity (FVC), Best measure	1.28	6	3	6.7	-0.68	1.3e-01	ABO NOP58 PVRL2 RGS12 SIK3 SMARCA4
Hypothyroidism (self reported)	1.27	4	1	2.2	0.27	7.3e-01	DDX56 NTN5 RGS12 SIK3
Birth weight	1.26	1	0	0.0	0.00	1.0e+00	NTN5
Relative age of first facial hair	1.24	1	1	2.2	0.00	1.0e+00	FNDC4
Impedance of leg (right)	1.24	8	6	13.3	0.37	3.3e-01	ABO AMIGO1 ATP13A1 ATXN7L2 FNDC4 HMGCR RGS19 TMEM133
Chronotype (morning person)	1.23	2	0	0.0	0.00	1.0e+00	AMIGO1 ZNF285
Hypothyroidism/myxoedema (self-reported)	1.23	1	0	0.0	0.00	1.0e+00	SIK3
Asthma	1.22	2	0	0.0	0.00	1.0e+00	MRPL38 SMARCA4
Impedance of arm (left)	1.22	5	3	6.7	0.80	1.0e-01	ATXN7L2 FNDC4 HMGCR KANK2 UBXN2B
Medication: Omeprazole	1.22	1	0	0.0	0.00	1.0e+00	DNAH11
Hayfever, allergic rhinitis or eczema	1.21	1	0	0.0	0.00	1.0e+00	PVRL2
Forced vital capacity (FVC)	1.21	7	4	8.9	-0.55	2.1e-01	ABO NOP58 PVRL2 RGS12 SIK3 SMARCA4 TMEM133
Asthma (self-reported)	1.21	1	0	0.0	0.00	1.0e+00	MRPL38
Relative age voice broke	1.20	1	0	0.0	0.00	1.0e+00	C12orf27
Standing height	1.20	18	12	26.7	-0.59	4.8e-03	ABCG5 APOC2 APOC4 ATP13A1 CELSR2 FNDC4 KANK2 MKRN2 MRPL45P2 NOP58 NTN5 PIGV PSRC1 RGS12 SLC22A3 SMARCA4 SPC24 TSEN2
Height	1.19	26	18	40.0	-0.63	8.9e-05	ABCG5 ABO APOC2 APOC4 ATP13A1 C12orf27 CELSR2 FNDC4 GPSM2 KANK2 LPL MKRN2 MRPL45P2 NOP58 NTN5 PIGV PSRC1 RAB3IL1 RGS12 SLC22A3 SMARCA4 SPC24 TMEM133 TSEN2 ZNF229 ZNF259
Impedance of arm (right)	1.19	7	3	6.7	0.79	3.4e-02	ATXN7L2 FNDC4 HMGCR KANK2 MRPL45P2 NTN5 UBXN2B
Impedance of whole body	1.19	7	4	8.9	0.76	4.8e-02	AMIGO1 ATP13A1 ATXN7L2 FNDC4 HMGCR RGS19 TMEM133
HbA1C	1.18	1	0	0.0	0.00	1.0e+00	ABO
Medication: Lisinopril	1.18	1	0	0.0	0.00	1.0e+00	TMEM133
Chronic bronchitis/emphysema (mother)	1.16	1	0	0.0	0.00	1.0e+00	BCAM
Lung FVC	1.15	8	4	8.9	-0.65	7.9e-02	ABO NOP58 PVRL2 RAB3IL1 RGS12 RGS19 SIDT2 SIK3
Medication: Omeprazole (e.g. Zanprol)	1.15	1	0	0.0	0.00	1.0e+00	DNAH11
Verbal and Numeric Reasoning (VNR)	1.14	1	0	0.0	0.00	1.0e+00	ATXN7L2
Irritable Bowel Disease (IBD)	1.13	1	1	2.2	0.00	1.0e+00	FNDC4
Forced expiratory volume in 1-second (FEV1)	1.13	5	1	2.2	-0.47	4.3e-01	ABO PVRL2 RGS12 SMARCA4 TMEM133
Had menopause	1.12	1	0	0.0	0.00	1.0e+00	LPL
Had other major operations	1.12	1	0	0.0	0.00	1.0e+00	ABCG5
Intelligence (Savage-Jansen 2018)	1.11	4	0	0.0	-0.72	2.8e-01	AMIGO1 ATXN7L2 DDX56 TXNL4B
Forced expiratory volume in 1-second (FEV1), Best measure	1.10	5	1	2.2	-0.48	4.2e-01	ABO PVRL2 RGS12 SMARCA4 TMEM133
Hand grip strength (left)	1.09	1	0	0.0	0.00	1.0e+00	PVRL2
Health satisfaction	1.07	1	0	0.0	0.00	1.0e+00	GPSM2
Bipolar Disorder or Schizophrenia	1.06	2	0	0.0	0.00	1.0e+00	ATP13A1 NTN5
Crohns Disease (2012)	1.06	1	0	0.0	0.00	1.0e+00	DOCK7
Hand grip strength (right)	1.06	1	0	0.0	0.00	1.0e+00	PVRL2
Age when periods started (menarche)	1.05	4	0	0.0	-0.48	5.2e-01	C12orf27 C12orf43 NOP58 NTN5
Peak expiratory flow (PEF)	1.05	2	1	2.2	0.00	1.0e+00	ABO NTN5
Comparative body size at age 10	1.04	2	0	0.0	0.00	1.0e+00	ATP13A1 NTN5
Schizophrenia vs Biploar Disorder	1.01	1	0	0.0	0.00	1.0e+00	FNDC4
Ulcerative Colitis (UC)	1.01	1	0	0.0	0.00	1.0e+00	RGS19
Mood swings	1.01	1	0	0.0	0.00	1.0e+00	AMIGO1
Nervous feelings	0.98	1	0	0.0	0.00	1.0e+00	C12orf43
Schizophrenia (2018)	0.97	1	0	0.0	0.00	1.0e+00	ATP13A1
Lung FEV1/FVC ratio	0.96	6	3	6.7	0.12	8.3e-01	CELSR2 HP NTN5 PSRC1 SIK3 TMEM133
Sitting height	0.96	12	2	4.4	-0.49	1.1e-01	ABCG5 ABO AMIGO1 ATP13A1 FNDC4 KANK2 MRPL45P2 NTN5 RGS12 SLC22A3 SPC24 TXNL4B
Reaction Time	0.94	1	0	0.0	0.00	1.0e+00	SMARCA4
Schizophrenia (2014)	0.94	1	0	0.0	0.00	1.0e+00	ATP13A1
Qualifications: A levels/AS levels or equivalent	0.94	2	0	0.0	0.00	1.0e+00	C12orf43 RGS12
Qualifications: College or University degree	0.93	3	1	2.2	0.00	1.0e+00	ATXN7L2 DNAH11 RGS12
Sensitivity / hurt feelings	0.92	1	0	0.0	0.00	1.0e+00	ATP13A1
Mouth/teeth dental problems: Dentures	0.92	1	0	0.0	0.00	1.0e+00	NTN5
Mouth/teeth dental problems	0.89	1	0	0.0	0.00	1.0e+00	NTN5
Irritability	0.89	1	0	0.0	0.00	1.0e+00	ATP13A1
Number of incorrect matches in round	0.88	1	0	0.0	0.00	1.0e+00	NAT2
Heel T-Score	0.87	9	4	8.9	-0.56	1.1e-01	ABO ATP13A1 ATXN7L2 CELSR2 HP PCSK7 TMEM133 TSEN2 ZHX3
Heel bone mineral density (BMD) T-score, automated (right)	0.87	1	0	0.0	0.00	1.0e+00	ABO
Number of operations (self-reported)	0.87	1	0	0.0	0.00	1.0e+00	ABCG5
Heel bone mineral density (BMD) T-score, automated (left)	0.78	1	0	0.0	0.00	1.0e+00	ABO
Worry too long after embarrassment	0.78	1	0	0.0	0.00	1.0e+00	RGS12
Neuroticism	0.73	1	0	0.0	0.00	1.0e+00	AMIGO1
Hair/balding pattern: Pattern 4	0.73	1	0	0.0	0.00	1.0e+00	ZHX3
Neuroticism (Nagel 2018)	0.67	1	0	0.0	0.00	1.0e+00	SLC22A1
Tanning	0.23	1	1	2.2	0.00	1.0e+00	FNDC4
Hair Pigment	0.22	8	2	4.4	0.64	3.4e-02	C12orf43 DHX38 FNDC4 MKRN2 PIGV SIDT2 SMARCA4 TMEM133

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	8	0.72	2.6
GTEx	Liver	5	0.70	2.4
The Cancer Genome Atlas	Colon Adenocarcinoma	12	0.58	2.1
GTEx	Whole Blood	9	0.45	2.0
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	8	0.50	2.0
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.39	2.0
GTEx	Esophagus Mucosa	16	0.48	1.9
GTEx	Muscle Skeletal	11	0.38	1.9
GTEx	Stomach	7	0.48	1.9
ROSMAP	Brain Pre-frontal Cortex	19	0.43	1.9
CommonMind	Brain Pre-frontal Cortex	24	0.45	1.9
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	2	0.18	1.9
The Cancer Genome Atlas	Glioblastoma Multiforme	5	0.49	1.9
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	8	0.39	1.9
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.29	1.9
The Cancer Genome Atlas	Stomach Adenocarcinoma	7	0.42	1.9
GTEx	Adipose Subcutaneous	7	0.20	1.8
GTEx	Adipose Visceral Omentum	7	0.34	1.8
GTEx	Adrenal Gland	6	0.41	1.8
GTEx	Artery Aorta	10	0.34	1.8
GTEx	Artery Tibial	16	0.43	1.8
GTEx	Brain Cortex	2	0.19	1.8
GTEx	Brain Frontal Cortex BA9	5	0.54	1.8
GTEx	Cells Transformed fibroblasts	18	0.43	1.8
GTEx	Esophagus Muscularis	12	0.37	1.8
GTEx	Ovary	3	0.33	1.8
GTEx	Skin Not Sun Exposed Suprapubic	9	0.37	1.8
GTEx	Skin Sun Exposed Lower leg	18	0.49	1.8
GTEx	Small Intestine Terminal Ileum	1	0.22	1.8
GTEx	Spleen	6	0.43	1.8
GTEx	Thyroid	10	0.25	1.8
GTEx	Vagina	2	0.31	1.8
YFS	Blood	14	0.30	1.8
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	12	0.44	1.8
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	15	0.37	1.8
The Cancer Genome Atlas	Brain Lower Grade Glioma	22	0.51	1.8
The Cancer Genome Atlas	Soft Tissue Sarcoma	5	0.47	1.8
The Cancer Genome Atlas	Thyroid Carcinoma	18	0.35	1.8
GTEx	Artery Coronary	2	0.17	1.7
GTEx	Brain Cerebellar Hemisphere	6	0.40	1.7
GTEx	Brain Cerebellum	4	0.20	1.7
GTEx	Breast Mammary Tissue (Female)	3	0.18	1.7
GTEx	Cells EBV-transformed lymphocytes	4	0.28	1.7
GTEx	Colon Sigmoid	4	0.27	1.7
GTEx	Colon Transverse	4	0.19	1.7
GTEx	Esophagus Gastroesophageal Junction	5	0.35	1.7
GTEx	Heart Atrial Appendage	3	0.19	1.7
GTEx	Heart Left Ventricle	3	0.20	1.7
GTEx	Lung	4	0.14	1.7
GTEx	Nerve Tibial	8	0.19	1.7
GTEx	Pancreas	3	0.18	1.7
GTEx	Pituitary	4	0.36	1.7
GTEx	Prostate	3	0.36	1.7
GTEx	Testis	6	0.19	1.7
METSIM	Adipose	17	0.37	1.7
NTR	Blood	8	0.33	1.7
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	7	0.42	1.7
The Cancer Genome Atlas	Breast Invasive Carcinoma	16	0.36	1.7
The Cancer Genome Atlas	Esophageal Carcinoma	4	0.58	1.7
The Cancer Genome Atlas	Lung Adenocarcinoma	7	0.24	1.7
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	7	0.28	1.7
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	4	0.24	1.7
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	4	0.30	1.7
The Cancer Genome Atlas	Prostate Adenocarcinoma	18	0.39	1.7
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.19	1.7
GTEx	Brain Caudate basal ganglia	2	0.22	1.6
GTEx	Brain Hippocampus	0	0.00	1.6
GTEx	Brain Nucleus accumbens basal ganglia	0	0.00	1.6
GTEx	Brain Putamen basal ganglia	0	0.00	1.6
GTEx	Breast Mammary Tissue	0	0.00	1.6
GTEx	Breast Mammary Tissue (Male)	3	0.25	1.6
GTEx	Uterus	0	0.00	1.6
The Cancer Genome Atlas	Testicular Germ Cell Tumors	2	0.16	1.6
GTEx	Brain Hypothalamus	1	0.17	1.5